Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Adjuvant Chemotherapy
9%
Adjuvant Therapy
9%
Adverse Event
31%
Arm
34%
B Cell
11%
B-Cell Chronic Lymphocytic Leukemia
11%
Bevacizumab
9%
Biological Marker
28%
Breast Cancer
84%
Brentuximab Vedotin
17%
Cancer
38%
Cancer Cell
10%
Cancer Therapy
13%
Carboplatin
11%
Carcinogenesis
9%
Chemoradiotherapy
16%
Chemotherapy
90%
Circulating Tumor DNA
18%
Cisplatin
18%
Classical Hodgkin Lymphoma
10%
Clinical Trial
50%
Colorectal Carcinoma
14%
Colorectal Liver Metastasis
10%
Connective Tissue Cancer
17%
Cyclophosphamide
14%
Diffuse Large B-Cell Lymphoma
23%
Disease Exacerbation
11%
Disease Free Survival
12%
Diseases
100%
Docetaxel
14%
Doxorubicin
22%
Drug Megadose
10%
Epidermal Growth Factor Receptor
14%
Estrogen Receptor
10%
Etoposide
11%
Follicular Lymphoma
18%
Gemcitabine
15%
Genetics
36%
Glioblastoma
11%
Hazard Ratio
26%
Head and Neck Cancer
10%
Head and Neck Squamous Cell Carcinoma
9%
Health Care Cost
10%
Histology
11%
Hodgkin's Lymphoma
27%
Hormone Receptor
8%
Hormone Therapy
14%
Human Immunodeficiency Virus
10%
Immune Checkpoint Inhibitor
14%
Immunotherapy
28%
Large-Cell Lymphoma
8%
Lung
8%
Lung Cancer
30%
Malignant Neoplasm
86%
Mantle Cell Lymphoma
23%
Median Follow Up
17%
Melanoma
15%
Metastatic Breast Cancer
23%
Metastatic Carcinoma
20%
Multiple Myeloma
13%
Neoadjuvant Chemotherapy
10%
Neoplasm
74%
Non Small Cell Lung Cancer
82%
Non-Hodgkin Lymphoma
24%
Odds Ratio
9%
Oncology
41%
Oral
11%
Overall Survival
98%
Paclitaxel
13%
Pancreas Adenocarcinoma
13%
Pancreas Cancer
13%
Pembrolizumab
14%
Peripheral T-Cell Lymphoma
15%
Phase II Trials
19%
Placebo
14%
Platinum
14%
Positron Emission Tomography
15%
Prognostic Factor
9%
Progression Free Survival
65%
Prostate Cancer
19%
Quality of Life
14%
Radiation Therapy
44%
Rectum Cancer
10%
Recurrent Disease
28%
Rituximab
30%
Small Cell Lung Cancer
14%
Soft Tissue Sarcoma
14%
Solid Malignant Neoplasm
16%
Squamous Cell Carcinoma
10%
Stem Cell Transplant
9%
Survival Rate
12%
Systematic Review
9%
Systemic Therapy
17%
T Cell
18%
Targeted Therapy
27%
Treatment Option
12%
Triple Negative Breast Cancer
14%
Tumor
49%
Tumor Progression
9%
Vincristine
9%
Keyphrases
95% Confidence Interval
45%
Adverse Events
22%
Antitumor Activity
14%
Autologous Stem Cell Transplantation (auto-SCT)
14%
Bendamustine
13%
Bevacizumab
15%
Breast Cancer
59%
Brentuximab Vedotin
23%
Cancer Treatment
11%
Carboplatin
15%
Cetuximab
12%
Chemotherapy
57%
Circulating Tumor DNA (ctDNA)
21%
Cisplatin
20%
Clinical Outcomes
18%
Clinical Trials
33%
Colorectal Cancer
14%
Colorectal Cancer Liver Metastasis (CRCLM)
13%
Complete Response
19%
Cyclin-dependent Kinase 4 (CDK4)
12%
Cyclophosphamide
15%
Diffuse Large B-cell Lymphoma (DLBCL)
21%
Disease Progression
15%
Docetaxel
19%
Dose Escalation
16%
Doxorubicin
24%
Duration of Response
12%
Follicular Lymphoma
22%
Gemcitabine
19%
Genome Analysis
14%
Glioblastoma
17%
Hazard Ratio
28%
Head-and-neck Cancer
13%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
18%
High Risk
15%
Hodgkin Lymphoma
16%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Immune Checkpoint Inhibitors
20%
In Cancer
21%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
30%
Lung Cancer
30%
Lymphoma
12%
Malignancy
12%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
12%
Mantle Cell Lymphoma
24%
Maximum Tolerated Dose
12%
Median Overall Survival
18%
Median Progression-free Survival
17%
Melanoma
17%
Metastasis
12%
Metastatic Breast Cancer
25%
Monotherapy
17%
Multiple Myeloma
12%
NCCN Guidelines
22%
Neutropenia
12%
Nivolumab
12%
Non-Hodgkin Lymphoma
16%
Non-small Cell Lung Cancer (NSCLC)
64%
Objective Response Rate
16%
Older Adults
14%
Oncology
19%
Overall Response Rate
18%
Overall Survival
78%
Paclitaxel
16%
Pan-cancer Analysis
12%
Pancreatic Cancer
16%
Pancreatic Ductal Adenocarcinoma
14%
Partial Response
19%
Patient Outcomes
12%
Pembrolizumab
19%
Peripheral T-cell Lymphoma
12%
Phase I Study
72%
Phase I Trial
16%
Phase II Trial
48%
Placebo
15%
Previously Treated
17%
Programmed Death-ligand 1 (PD-L1)
14%
Progression-free Survival
51%
Radiation Therapy
25%
Radiotherapy
12%
Randomized Phase II Trial
14%
Relapsed/refractory
33%
Resection
13%
Response Rate
14%
Rituximab
33%
Sarcoma
14%
Small Cell Lung Cancer
15%
Solid Tumors
14%
Stable Disease
15%
Standard of Care
12%
Systemic Therapy
14%
T Cells
16%
Targeted Therapy
27%
Treatment Options
12%
Treatment-related Adverse Events
13%
Triple-negative Breast Cancer
19%
Tumor
79%
Tumor Cells
13%
United States
12%
Well Tolerated
16%